A specific study pointed out that when rituximab blocks CD20, moesin will be selectively recruited to the CD20 cap, leading to polarization of cancer cells, and this polarization increased the frequency of NK cells killing target cells through ADCC by 60% compared with the non-polarization [26]. This evidence concerns the gene MSN and cancer.